2026 Clinical Development Disease Therapies 
Drug Discovery World
OCTOBER 4, 2024
Huntington’s disease is an autosomal dominant neurodegenerative disorder for which there is currently no disease modifying treatment available. The company is hoping to enter the clinic in 2026.
Drug Discovery World
OCTOBER 4, 2022
This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 12, 2020
Dedicated rare disease unit to be headquartered in Boston. Pascal Soriot , Chief Executive Officer, AstraZeneca , said: “ Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology.
The Pharma Data
JUNE 2, 2022
Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above.
The Pharma Data
MAY 31, 2022
Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. pneumoniae invasive disease and pneumonia in adults 50 years and above. Pneumococcal disease.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. Rare Disease. BNT162 mRNA-based Vaccine Program.
Expert insights. Personalized for you.
147 
Let's personalize your content